<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B936D768-A528-4ABB-A6FA-D5F91D6FD0F4"><gtr:id>B936D768-A528-4ABB-A6FA-D5F91D6FD0F4</gtr:id><gtr:name>Defence Science &amp; Technology Laboratory (DSTL)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D4FF7C8F-C29F-420F-A626-2348EA059004"><gtr:id>D4FF7C8F-C29F-420F-A626-2348EA059004</gtr:id><gtr:name>Novacta Biosystems Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B2D2D3F7-47FA-40EE-A7BE-C4AC26976EB4"><gtr:id>B2D2D3F7-47FA-40EE-A7BE-C4AC26976EB4</gtr:id><gtr:name>Cubist Pharmaceuticals</gtr:name><gtr:address><gtr:line1>65. Hayden Avenue</gtr:line1><gtr:postCode>02421</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AC6D202D-0207-4DE7-AED8-2C5093A27909"><gtr:id>AC6D202D-0207-4DE7-AED8-2C5093A27909</gtr:id><gtr:name>Vita-Salute San Raffaele University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DD8042D9-E20B-4415-8883-53B0C63EAC7D"><gtr:id>DD8042D9-E20B-4415-8883-53B0C63EAC7D</gtr:id><gtr:name>Basilea Pharmaceutica</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B936D768-A528-4ABB-A6FA-D5F91D6FD0F4"><gtr:id>B936D768-A528-4ABB-A6FA-D5F91D6FD0F4</gtr:id><gtr:name>Defence Science &amp; Technology Laboratory (DSTL)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D4FF7C8F-C29F-420F-A626-2348EA059004"><gtr:id>D4FF7C8F-C29F-420F-A626-2348EA059004</gtr:id><gtr:name>Novacta Biosystems Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B2D2D3F7-47FA-40EE-A7BE-C4AC26976EB4"><gtr:id>B2D2D3F7-47FA-40EE-A7BE-C4AC26976EB4</gtr:id><gtr:name>Cubist Pharmaceuticals</gtr:name><gtr:address><gtr:line1>65. Hayden Avenue</gtr:line1><gtr:postCode>02421</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AC6D202D-0207-4DE7-AED8-2C5093A27909"><gtr:id>AC6D202D-0207-4DE7-AED8-2C5093A27909</gtr:id><gtr:name>Vita-Salute San Raffaele University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DD8042D9-E20B-4415-8883-53B0C63EAC7D"><gtr:id>DD8042D9-E20B-4415-8883-53B0C63EAC7D</gtr:id><gtr:name>Basilea Pharmaceutica</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/18399BAB-0F5F-40AC-A58F-4E46BED16C50"><gtr:id>18399BAB-0F5F-40AC-A58F-4E46BED16C50</gtr:id><gtr:firstName>Simon J.</gtr:firstName><gtr:surname>Foster</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/39EEFBC4-3441-41A3-BE79-0DBA4F037BA5"><gtr:id>39EEFBC4-3441-41A3-BE79-0DBA4F037BA5</gtr:id><gtr:firstName>Luke</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Alderwick</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DC3E968D-06C2-4F03-9987-D58301F99BC6"><gtr:id>DC3E968D-06C2-4F03-9987-D58301F99BC6</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Gerrard</gtr:otherNames><gtr:surname>Dowson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/81141413-9AE6-4662-BD73-F91C42871C65"><gtr:id>81141413-9AE6-4662-BD73-F91C42871C65</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Lloyd</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/485FE68A-8E09-4545-A568-7DF4B42DC7B4"><gtr:id>485FE68A-8E09-4545-A568-7DF4B42DC7B4</gtr:id><gtr:firstName>Waldemar</gtr:firstName><gtr:surname>Vollmer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9729A4DB-2FB1-40BC-8B89-E8FA153AD4C2"><gtr:id>9729A4DB-2FB1-40BC-8B89-E8FA153AD4C2</gtr:id><gtr:firstName>Gurdyal Singh</gtr:firstName><gtr:surname>Besra</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1FD4D789-FFE2-40DF-91BF-73143F6A553A"><gtr:id>1FD4D789-FFE2-40DF-91BF-73143F6A553A</gtr:id><gtr:firstName>David Ian</gtr:firstName><gtr:surname>Roper</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DDBB3F10-D3B5-4C13-BD8E-415EF8EBE9C9"><gtr:id>DDBB3F10-D3B5-4C13-BD8E-415EF8EBE9C9</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:otherNames>David Howard</gtr:otherNames><gtr:surname>Bugg</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1100127"><gtr:id>A6DDFBF7-F9DD-47FA-96D2-E4D55F5A63BF</gtr:id><gtr:title>Team CanUK: Novel antibacterial targets, assays, probes and opportunities in bacterial cell wall biogenesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100127</gtr:grantReference><gtr:abstractText>Millions of people die each year from bacterial infections and tens of millions suffer from the consequences of these infections. The discovery of the antibiotic penicillin once opened the door to treat these infections by stopping bacteria making the polymer in the cell wall that holds them together. This polymer, called peptidoglycan, is made up of an interlocking network of sugars and strings of amino acids (peptides). Specialised proteins (called PBPs), with the ability to stitch together these sugars and peptides are the targets inhibited by penicillin, stopping cell wall synthesis and killing the bacterium. Many important bacteria are no longer killed by penicillin and other antibiotics that attack other stages in the production of peptidoglycan. Bacteria have changed, evading the action of these antibiotics. We need to fight back. Our progress until recently has been hampered by our inability to routinely synthesise the key chemical components that make this polymer. We can now do this. This is exciting, as we develop the capability to explore important unanswered questions about how bacteria grow and control the production of peptidoglycan. We wish to pull together the expertise of UK and Canadian scientists in a cooperative and coordinated partnership to increase our understanding of the fundamental biology of this process. All of this will open fundamentally new biological insights, and opportunities to use these for the future development of new antibiotics that will work against multiply antibiotic resistant bacteria like MRSA and TB.</gtr:abstractText><gtr:technicalSummary>There is a currently a global health threat posed by emerging antibiotic resistance amongst clinically important bacteria which is compounded by the decline in new drugs coming to the market. The bacterial cell wall (peptidoglycan, PG) is a validated, important, target for existing antibiotics and is a fundamental biological process, which is still poorly understood. Previous MRC funding in the UK has been used to create a research network focussed on PG with a synthesis facility at Warwick. This facility provides bespoke PG reagents to the research community that are not available commercially and has been a significant breakthrough in our capacity to address unanswered questions within the pathway. Researchers in Canada also have a track record of research in this area along with facilities for high throughput screening and compound libraries that can take advantage of new assays and substrates. The purpose of this UK-Canada network is thus to facilitate the development of bilateral research programmes with the aim of unravelling key features of bacterial cell wall biosynthesis using an integrated approach in which cell wall are analysed in a hierarchical manner from the fundamental biochemistry of peptidoglycan biochemistry, through sub-cellular organisation of the assembly machinery, to cell polymerisation. The aims are to understand the interrelationships between the formation of precursors, their export, polymerisation, modification and recycling to inform our fundamental understanding of the system. Overarching this is a desire to use this information in a rational manner to ultimately develop novel antimicrobials and identify new antimicrobial targets.</gtr:technicalSummary><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>995684</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cubist Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CAN UK Industry partner</gtr:description><gtr:id>8C3ED669-622D-431E-ADB1-0AF10988CA77</gtr:id><gtr:impact>Successful BBSRC LINK grant with Astra Zeneca - total value &amp;pound;1.1M</gtr:impact><gtr:partnerContribution>Research funds, in kind support (&amp;pound;290000 from AZ), and advice plus support for future pending grant applications</gtr:partnerContribution><gtr:piContribution>Supply of reagents and advice around assay design and development</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Infection</gtr:department><gtr:description>CAN UK Industry partner</gtr:description><gtr:id>D0E245F2-D5CB-4823-BDCF-BEB844F73B66</gtr:id><gtr:impact>Successful BBSRC LINK grant with Astra Zeneca - total value &amp;pound;1.1M</gtr:impact><gtr:partnerContribution>Research funds, in kind support (&amp;pound;290000 from AZ), and advice plus support for future pending grant applications</gtr:partnerContribution><gtr:piContribution>Supply of reagents and advice around assay design and development</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vita-Salute San Raffaele University</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Developing new reagents to underpin pharmaceutic research</gtr:description><gtr:id>38660A73-8712-467C-BA09-CE7DA30D7462</gtr:id><gtr:impact>knowledge transfer</gtr:impact><gtr:partnerContribution>Discussion and insight into screening strategies and fundamental science underpinning antibiotic discovery</gtr:partnerContribution><gtr:piContribution>Provision of reagents as biological standards to help inform assay development</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Astra Zeneca global screening platform</gtr:description><gtr:id>CDC4B040-23CC-4553-AB1E-E2AD222DED24</gtr:id><gtr:impact>Novel assay development and assay validation
Hit screening underway</gtr:impact><gtr:partnerContribution>Advice, knowledge transfer, training and access to high throughput screening platforms and chemical libraries</gtr:partnerContribution><gtr:piContribution>Knowledge transfer, biological insight and assay development</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novacta Biosystems Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novacta</gtr:description><gtr:id>9654A800-28A0-482D-AE85-EAB0CBE80880</gtr:id><gtr:impact>Novacta became industrial advisors as part of our MRC programme grant application and Mike Dawson from Novacta still performs this function</gtr:impact><gtr:partnerContribution>Indistrial focussed advice</gtr:partnerContribution><gtr:piContribution>updating company on our assay development and screening capabilities</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Defence Science &amp; Technology Laboratory (DSTL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Underpinning technology to exploit peptidoglycan biosynthesis</gtr:description><gtr:id>F2A28AF6-8284-4A4E-83F2-21606C2FB7CF</gtr:id><gtr:impact>too early - completing initial contracting process</gtr:impact><gtr:partnerContribution>Insight into defence requirements and work leading up to the project</gtr:partnerContribution><gtr:piContribution>Insight into the assembly of the cytoplasmic phase of peptidoglycan biosynthesis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Infectious Diseases</gtr:department><gtr:description>CAN UK Industry partner</gtr:description><gtr:id>32046B3B-9E03-4393-B4A5-DE3F62379A92</gtr:id><gtr:impact>Successful BBSRC LINK grant with Astra Zeneca - total value &amp;pound;1.1M</gtr:impact><gtr:partnerContribution>Research funds, in kind support (&amp;pound;290000 from AZ), and advice plus support for future pending grant applications</gtr:partnerContribution><gtr:piContribution>Supply of reagents and advice around assay design and development</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cubist Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Exploring peptidoglycan polymerization</gtr:description><gtr:id>225F8288-3A4F-4F41-BEDD-AE7AEB776E39</gtr:id><gtr:impact>Have obtained letters of support from Cubist for recent grant applications and developed a good working relationship with their senior scientists</gtr:impact><gtr:partnerContribution>iterative feedback on assay development and outcome</gtr:partnerContribution><gtr:piContribution>Provision of commercially unavailable reagents and knowhow to assist in assay development</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research and Development AstraZeneca</gtr:department><gtr:description>New assays and reagents to exploit peptidoglycan biosynthesis</gtr:description><gtr:id>0EA9DEAD-4A7E-4150-B377-6D4D6D53F9B9</gtr:id><gtr:impact>Wider collaboration with other global pharma, new grant applications, increased industrial understanding, training and skills for researchers and students</gtr:impact><gtr:partnerContribution>Insight into establishment of high throughput screening approaches, pitfalls and access to equipment</gtr:partnerContribution><gtr:piContribution>Development of new reagents and assays</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Basilea Pharmaceutica</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Peptidoglycan flux and inhibition</gtr:description><gtr:id>C16B53B0-46DD-43EA-8B7A-5C088730999A</gtr:id><gtr:impact>Knowledge transfer</gtr:impact><gtr:partnerContribution>Historical insight and approaches to targeting these enzymes</gtr:partnerContribution><gtr:piContribution>Developing new insight into the ealy stages of peptidoglycan biosynthesis and how protein protein interaction may impact upon ability to inhibit these reactions</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Basilea Pharmaceutica</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>CAN UK Industry partner</gtr:description><gtr:id>FE289030-CC6C-4CB4-9352-E7D6973ECB4D</gtr:id><gtr:impact>Successful BBSRC LINK grant with Astra Zeneca - total value &amp;pound;1.1M</gtr:impact><gtr:partnerContribution>Research funds, in kind support (&amp;pound;290000 from AZ), and advice plus support for future pending grant applications</gtr:partnerContribution><gtr:piContribution>Supply of reagents and advice around assay design and development</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRCT Centre for Therapeutics Discovery (CTD)</gtr:department><gtr:description>MRCT</gtr:description><gtr:id>6E1E6298-69EE-4F63-8495-442CDAEF630B</gtr:id><gtr:impact>DPFS grant applications</gtr:impact><gtr:partnerContribution>Pump priming drug discovery research and further grant applications to MRC</gtr:partnerContribution><gtr:piContribution>Provision of reagents and assays, developing structural information</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Virtual reality E. coli</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>52D72335-4269-42C0-90A3-24E73840CEA1</gtr:id><gtr:impact>We developed a virtual reality E. coli experience that was used at Festival of the Mind in September 2016. Hugely successful.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ANTRUK Antibiotic Research UK</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>350607B4-0218-49FA-982C-BA831CD89AB7</gtr:id><gtr:impact>Establishment of new charity and new fundraising campaign

regional and national media interest</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.antibioticresearch.org.uk</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Regional news papers</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8C70B61F-5E2C-4289-906A-D305FA860047</gtr:id><gtr:impact>Contribution to regional news

Further contacts from regional and national media</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2006,2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Getting to grips with antibiotic resistance</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C92B3DCD-630B-47F5-9058-5254A3BD2CCC</gtr:id><gtr:impact>The School of Life Sciences at Warwick hosted members of the public and press for a presentational evening with talks, lab tours and demonstrations in an event entitled: &amp;quot;Getting to grips with antibiotic resistance&amp;quot; This event was held in antibiotic awareness week in November 2016 and hosted around 90 visitor</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www2.warwick.ac.uk/fac/sci/lifesci/outreach/next/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>O'Neil AMR review</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F0043450-D561-4088-AA6E-A8FB8B6CB6FA</gtr:id><gtr:impact>In December we published our first report1
 showing that infections caused by
drug-resistant pathogens are one of the biggest health problems the world faces
today. Bacteria and other pathogens have always evolved to resist the new drugs
that modern medicine uses to combat them. But in recent years the rise in drug
resistance has been a particular worry, especially the emergence of antibioticresistant
superbugs. Unless action is taken to address this huge global issue, our
conservative estimate is that it will cost the world an additional 10 million lives
a year by 2050, more than the number of people currently dying from cancer
annually. It will also have a cumulative cost of 100 trillion USD, more than one
and a half times annual world GDP today, or roughly the equivalent to losing the
UK economy from global output every year.
We now turn our attention to how this problem can be tackled. This paper is the
first in a series that works towards global and sustainable solutions. There are
many angles to the problem that we will need more time to consider. In particular,
the focus of our next paper, due to be published in the spring, will be how to
stimulate the market for companies to invest in and develop new antimicrobials and
diagnostics, which is not fully addressed here. There we will assess potential 'push'
and 'pull' incentives to encourage the development of new antimicrobial drugs,
and set out our proposals for action by policy makers. In later papers we will also
focus on important issues such as the use of antibiotics in agriculture and potential
alternatives to antimicrobials</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>https://amr-review.org/sites/default/files/Report-52.15.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Warwick University iCAST</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F75AAC9E-0772-4845-B828-5D5C4B20952B</gtr:id><gtr:impact>Communication to UK and global audience

Further media contacts</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pew Road Map for Antibiotic Discovery</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C48B2A7C-7B4A-42ED-961F-22295451DEEA</gtr:id><gtr:impact>The Pew Charitable Trusts convened a multidisciplinary group of leading industry and academic experts to
identify the key scientific roadblocks to antibiotic discovery and consulted with numerous other public and
private sector stakeholders to develop a Scientific Roadmap for Antibiotic Discovery. The roadmap outlines a
concrete approach-both a scientific plan and organizational structure to support this research-that would lay a
foundation for the sustained and diversified discovery and development of new antibiotics and therapies over the
coming decades.The report's key findings show a need for:
? A targeted approach to tackle the basic scientific barriers impeding antibiotic discovery and development.
? A better understanding of how to overcome the cellular defenses of drug-resistant Gram-negative bacteria,
which cause some of the most difficult-to-treat infections.
? Generation of new chemical matter designed for antibiotic discovery.
? Tools and methodologies to evaluate promising alternatives to traditional antibiotic use.
? A framework for sharing information, expertise, and materials across the research community to foster
innovative science and spur the discovery of novel antibacterial therapies.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://www.pewtrusts.org/~/media/assets/2016/05/ascientificroadmapforantibioticdiscovery.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Shambala Festival August 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>856AC0F7-FCBE-42BD-B71F-52F3AFB1616F</gtr:id><gtr:impact>Krebsfest went on tour to the Shambala Festival with series of talks and workshops.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Flemming video</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FBDA9234-47BE-4708-BC96-F76CFF38594E</gtr:id><gtr:impact>100000. Short film presentation linking our current MRC funded research to the groundbreaking work by alexander Flemming

to be released later this year as part of the MRC celebrations</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>flexible interchange partnership FLIP</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>A7245F82-8A5E-47AF-947C-227DBAF0C803</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>464000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC LINK award</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K017268/1</gtr:fundingRef><gtr:id>49B6B7F1-09C4-44D8-89D7-2B3FA890AB12</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC AMR theme 1 collaboration award</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D608D73D-4B28-4371-A327-ED61CCD85886</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Coventry General Charities</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>General Charity of the City of Coventry</gtr:fundingOrg><gtr:id>5FE6D350-FBBD-4C1E-B21A-1BE95A7F355E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Accelerate CHNUK AMR discovery: Establishing joint China/UK training and research platforms enabling highthroughput fragment based inhibitor discovery</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>Newton Fund</gtr:fundingOrg><gtr:fundingRef>MR/P007503/1	</gtr:fundingRef><gtr:id>E9FAFDFF-1053-4568-AA0E-A43CE23C478F</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical and Life Sciences Research Fund</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Medical and Life Sciences Research Fund</gtr:fundingOrg><gtr:id>7DE061FE-928F-4D01-A50D-78103EFC782F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Optimisation of peptidoglycan pathway intermediates synthesis and purification</gtr:description><gtr:id>9DAF26CE-1237-45DC-AE1F-87BB070F602D</gtr:id><gtr:impact>Development of a synthesis facility to provide thes eintemediates to the global research community and the fundamental platform for several UK and international peptidoglycan networks</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Synthesis of peptidoglycan intermediates</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lessons to be learnt from pharma A summary of an interactive one-day symposium about discovery and development of new antibacterial drugs 1 Lessons to be learnt from pharma about discovery and development of new antibacterial drugs</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4BDE77A9-7457-4ADF-9429-F040C1C2D480</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Canada/UK AMR Workshop</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>52018681-DDCC-43AD-8612-5E3FFE516FD3</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>All Party Parliamentary Group on Antimicrobial Resistance</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A11E1560-7A58-4D2B-BE84-8358CAF5F941</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC strategic review on antimicrobial resistance</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>09A9665B-090B-499E-84B8-49FE89E10362</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>First in class continuous quantitative bifunctional PBP assay</gtr:description><gtr:id>0C20B770-A172-4B51-A8C1-A276A4C34A7F</gtr:id><gtr:impact>Use in HTS assay with Astra Zeneca</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>New assays for penicillin binding proteins</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>new continuous assay for drug discovery</gtr:description><gtr:id>1BD329CB-2763-4B16-B522-C5ED620FE591</gtr:id><gtr:impact>new tools for pharma</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>tRNA synthetase assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Capacity to synthesise peptidoglycan intermediates at high purity and semi-commercial quantities</gtr:description><gtr:id>92DC1F0C-A958-429A-A109-2104173DF489</gtr:id><gtr:impact>Access of reagents to the wider community - supplied over 40 research groups worldwide</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>peptidoglycan pathway intermediates</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Antimicrobial Discovery Solutions Ltd</gtr:companyName><gtr:description>Reagents, assay development and services</gtr:description><gtr:id>6605070C-3142-4BD7-80FE-86A2446C86CC</gtr:id><gtr:impact>N/A</gtr:impact><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/073BE1F9-60AE-4B7C-A32E-8E93E37B9971"><gtr:id>073BE1F9-60AE-4B7C-A32E-8E93E37B9971</gtr:id><gtr:title>Lcp1 Is a Phosphotransferase Responsible for Ligating Arabinogalactan to Peptidoglycan in Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>mBio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c4a9d8f0267f332dce0445e50d0e7122"><gtr:id>c4a9d8f0267f332dce0445e50d0e7122</gtr:id><gtr:otherNames>Harrison J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF06215A-4FC1-4EFF-9BBE-8A692B5E8053"><gtr:id>AF06215A-4FC1-4EFF-9BBE-8A692B5E8053</gtr:id><gtr:title>Bacterial cell wall assembly: still an attractive antibacterial target.</gtr:title><gtr:parentPublicationTitle>Trends in biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f7a02442d81e889671ae7bb0cfefd6f"><gtr:id>5f7a02442d81e889671ae7bb0cfefd6f</gtr:id><gtr:otherNames>Bugg TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0167-7799</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD4ABB8B-A42D-4DAB-A4FA-1FAB28F32F6D"><gtr:id>FD4ABB8B-A42D-4DAB-A4FA-1FAB28F32F6D</gtr:id><gtr:title>Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4e93a23805972b417db19d67fd4fe977"><gtr:id>4e93a23805972b417db19d67fd4fe977</gtr:id><gtr:otherNames>Tran AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8DD269F8-BCC4-4DB0-B7BA-42E7BDD22563"><gtr:id>8DD269F8-BCC4-4DB0-B7BA-42E7BDD22563</gtr:id><gtr:title>Inhibition of phospho-MurNAc-pentapeptide translocase (MraY) by nucleoside natural product antibiotics, bacteriophage ?X174 lysis protein E, and cationic antibacterial peptides.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f7a02442d81e889671ae7bb0cfefd6f"><gtr:id>5f7a02442d81e889671ae7bb0cfefd6f</gtr:id><gtr:otherNames>Bugg TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/66499DD2-B22C-4FC7-9FFD-88CB4A9AB45F"><gtr:id>66499DD2-B22C-4FC7-9FFD-88CB4A9AB45F</gtr:id><gtr:title>Adenosine tetraphosphoadenosine drives a continuous ATP-release assay for aminoacyl-tRNA synthetases and other adenylate-forming enzymes.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7d9a44e5e7a61959fd7e4276275fb157"><gtr:id>7d9a44e5e7a61959fd7e4276275fb157</gtr:id><gtr:otherNames>Lloyd AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/217D8B21-D216-41FE-8A34-87E71085924F"><gtr:id>217D8B21-D216-41FE-8A34-87E71085924F</gtr:id><gtr:title>Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7afc5d17144907949d5694a64160a7b9"><gtr:id>7afc5d17144907949d5694a64160a7b9</gtr:id><gtr:otherNames>Zuegg J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E23D6A49-F84A-48F7-ACEC-4BDB976B91EC"><gtr:id>E23D6A49-F84A-48F7-ACEC-4BDB976B91EC</gtr:id><gtr:title>Indistinguishability and identifiability of kinetic models for the MurC reaction in peptidoglycan biosynthesis.</gtr:title><gtr:parentPublicationTitle>Computer methods and programs in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7fccc62dcb001da25a45d7759024342c"><gtr:id>7fccc62dcb001da25a45d7759024342c</gtr:id><gtr:otherNames>Hattersley JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0169-2607</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/45583E68-F78A-4566-9054-B4C86B98F52B"><gtr:id>45583E68-F78A-4566-9054-B4C86B98F52B</gtr:id><gtr:title>Core Steps of Membrane-Bound Peptidoglycan Biosynthesis: Recent Advances, Insight and Opportunities.</gtr:title><gtr:parentPublicationTitle>Antibiotics (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f98baa5319d785b8b6676b8f91f56aa"><gtr:id>6f98baa5319d785b8b6676b8f91f56aa</gtr:id><gtr:otherNames>Teo AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2079-6382</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2B2DDD43-812B-4E65-850A-A8A6C2845C1C"><gtr:id>2B2DDD43-812B-4E65-850A-A8A6C2845C1C</gtr:id><gtr:title>Crystallization and preliminary X-ray analysis of a UDP-MurNAc-tripeptide D-alanyl-D-alanine-adding enzyme (PaMurF) from Pseudomonas aeruginosa.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section F, Structural biology and crystallization communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e9763415119c5c44dee9e28a5692519d"><gtr:id>e9763415119c5c44dee9e28a5692519d</gtr:id><gtr:otherNames>Majce V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1744-3091</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4C831A81-C904-4379-999A-CB513BEE142C"><gtr:id>4C831A81-C904-4379-999A-CB513BEE142C</gtr:id><gtr:title>Specificity determinants for lysine incorporation in Staphylococcus aureus peptidoglycan as revealed by the structure of a MurE enzyme ternary complex.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dae6efc545e6199e3cca661a6f32476f"><gtr:id>dae6efc545e6199e3cca661a6f32476f</gtr:id><gtr:otherNames>Ruane KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100127</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>